Table 1

Study design and enrolment details of cohorts included in the MULTI sTUdy Diabetes rEsearch Consortium

Data setsStudy typeSample size (n)Follow-up timeSex (%)Race/ethnicityInclusion criteriaEnrolment age (years)Enrolled with diabetes* (n)
ACCORD21 Clinical trial10 2514–8 yearsM (61), F (39)W, B, H, OT2DM40–7910 251
AFFIRM34 Clinical trial40605 yearsM (61), F (39)W, OAtrial fibrillation≥65813
 Atrial fibrillation+stroke risk factor<65
BARI 2D22 Clinical trial23685 yearsM (70), F (30)W, B, H, AT2DM and CAD≥252368
ARIC35 Prospective cohort15 792Five examinations to dateM (45), F (55)W, BRandomly selected from four ARIC field centres in MD, NC, MS, MN45–641518
JHS36 Prospective cohort5302Three examinations to dateM (36), F (64)BRandomly selected from urban and rural areas of three counties in MS35–841152
FHS cohort20 Prospective cohort520932 examinations to dateM (45), F (55)WFramingham resident28–74109
FHS offspring20 Prospective cohort5124Nine examinations to dateM (48), F (52)WOffspring of FHS cohort or spouse of FHS offspring5–7077
FHS Gen320 Prospective cohort4095Two examinations to dateM (47), F (53)WAt least one parent in FHS offspring or one grandparent in FHS cohort19–72101
FOCUS24 Clinical trial201660 daysM (24), F (76)W, B, A, OHip surgery patient with clinical evidence for CVD≥50508
MRFIT37 Clinical trial12 8666–8 yearsM (100)W, BAt increased risk of death from CHD without clinical evidence of CHD35–57345
ALLHAT38 Clinical trial33 357;
10 355
4–8 yearsM (53), F (47)W, B, A, OHypertension and at least one other CHD risk factor≥5515 701
BHS39 Prospective cohort11 796Seven examinations to dateM (52), F (48)W, BRandomly selected from a biracial, semirural Louisiana community3–3733
CORAL40 Clinical trial94731–55 monthsM (51), F (49)W, BSevere renal-artery stenosis with a history of hypertension35–88310
NGHS41 Prospective cohort23799 yearsF (100)W, BRandomly selected from three clinic sites in California, Ohio and Maryland9–100
OMNI heart42 Clinical trial16418 weeksM (55), F (45)W, BPrehypertension or stage 1 hypertension, not medically managed≥304
POWER-UP43 Clinical trial39024 monthsM (20), F (80)W, B, A, BiBMI of 30–50 kg/m2 and at least two of five components of the metabolic syndrome≥2184
SPRINT-POP23 Clinical trial93613.26 yearsM (65), F (35)W, B, H, OHigh blood pressure without diabetes or a history of CVD≥5047
  • *T2DM is defined in our cohort consortium as a random plasma glucose concentration ≥200 mg/dL, which may differ from definitions within individual cohorts.

  • A, Asian; ACCORD, Action to Control Cardiovascular Risk in Diabetes; AFFIRM, Atrial Fibrillation Follow-Up Investigation of Rhythm Management; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ARIC, Atherosclerosis Risk in Communities; B, black; BARI 2D, Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes; BHS, Bogalusa Heart Study; Bi, biracial; BMI, body mass index; CAD, coronary artery disease; CHD, coronary heart disease; CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions; CVD, cardiovascular disease; F, female; FHS, Framingham Heart Study; FOCUS, Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair; H, Hispanic; JHS, Jackson Heart Study; M, male; MRFIT, Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease; NGHS, NHLBI Growth and Health Study; O, other; OMNI heart, Optimal Macronutrient Intake Trial to Prevent Heart Disease; POWER-UP, Practice Based Opportunities for Weight Reduction Trial at the University of Pennsylvania; SPRINT-POP, Systolic Blood Pressure Intervention Trial Primary Outcome Paper; T2DM, type 2 diabetes mellitus; W, white.